Back to Search
Start Over
Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients.
- Source :
-
Haematologica [Haematologica] 2014 Sep; Vol. 99 (9), pp. e159-61. Date of Electronic Publication: 2014 Jun 27. - Publication Year :
- 2014
- Subjects :
- Adolescent
Adult
Aged
Alemtuzumab
Bendamustine Hydrochloride
Drug Administration Schedule
Drug Combinations
Female
Humans
Injections, Intravenous
Injections, Subcutaneous
Leukemia, Lymphocytic, Chronic, B-Cell mortality
Leukemia, Lymphocytic, Chronic, B-Cell pathology
Male
Middle Aged
Recurrence
Survival Analysis
Treatment Outcome
Antibodies, Monoclonal, Humanized therapeutic use
Antineoplastic Agents, Alkylating therapeutic use
Leukemia, Lymphocytic, Chronic, B-Cell drug therapy
Nitrogen Mustard Compounds therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1592-8721
- Volume :
- 99
- Issue :
- 9
- Database :
- MEDLINE
- Journal :
- Haematologica
- Publication Type :
- Editorial & Opinion
- Accession number :
- 24972768
- Full Text :
- https://doi.org/10.3324/haematol.2014.106740